Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates.


Journal

Bioconjugate chemistry
ISSN: 1520-4812
Titre abrégé: Bioconjug Chem
Pays: United States
ID NLM: 9010319

Informations de publication

Date de publication:
24 Jan 2024
Historique:
medline: 24 1 2024
pubmed: 24 1 2024
entrez: 24 1 2024
Statut: aheadofprint

Résumé

Antibody-drug conjugates (ADCs) are an established modality that allow for targeted delivery of a potent molecule, or payload, to a desired site of action. ADCs, wherein the payload is a targeted protein degrader, are an emerging area in the field. Herein we describe our efforts of delivering a Bruton's tyrosine kinase (BTK) bifunctional degrader

Identifiants

pubmed: 38265691
doi: 10.1021/acs.bioconjchem.3c00535
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Alan Zhang (A)

Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States.

Katherine Seiss (K)

Oncology Biotherapeutics, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States.

Laurent Laborde (L)

Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Sebastian Palacio-Ramirez (S)

Novartis Biologics Center, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States.

Daniel Guthy (D)

Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Mylene Lanter (M)

Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Julien Lorber (J)

Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Anna Vulpetti (A)

Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Luca Arista (L)

Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Thomas Zoller (T)

Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Thomas Radimerski (T)

Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Claudio Thoma (C)

Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Christina Hebach (C)

Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

William R Tschantz (WR)

Novartis Biologics Center, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States.

Alexei Karpov (A)

Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Gregory J Hollingworth (GJ)

Global Discovery Chemistry, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Joseph A D'Alessio (JA)

Oncology Biotherapeutics, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States.

Stephane Ferretti (S)

Oncology, Novartis Biomedical Research, CH-4002 Basel, Switzerland.

Matthew T Burger (MT)

Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139 United States.

Classifications MeSH